Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity

SYDNEY, May 6, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, reports the discovery of the primary mechanism...